Vaccination by Homologous Antigenic Loading as Adjuvant Therapy for Glioblastoma: Phase I Clinical Trial Analysis
Time: 4:15 pm
day: Conference Day 1
Details:
- Developing a novel autologous dendritic cell therapy vaccine (DOC1021) as adjuvant therapy for GBM
- DOC1021 is safe, can be effectively integrated within existing standards of care and appears efficacious in a challenging patient population
- Strong correlations between vaccine genetic signature and peripheral immune responses were observed
- Analyzing the survival data Median survival of this 15/16 MGMTp unmethylated cohort has not yet been reached and is statistically greater (p<0.02) than that of matched historic controls after median 13.7 months follow-up
